Sugi Predict

Sugi Predict / Compounds / SCHEMBL1989474

SCHEMBL1989474

SCHEMBL1989474

CCOC(=O)c1cn(C2CC2)c2c(OC)c(F)c(F)cc2c1=O

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 P07550 1/20 0.61
▸ KCNH2 Q12809 4/20 0.52
▸ GSK3B P49841 2/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ ALDH1A1 P00352 3/20 0.51
▸ HPGD P15428 3/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ POLB P06746 1/20 0.51
▸ PRKD3 O94806 1/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ OPRM1 P35372 1/20 0.51
▸ CLK2 P49760 1/20 0.51
▸ CLK4 Q9HAZ1 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ STAT3 P40763 1/20 0.50
▸ TOP2A P11388 2/20 0.48
▸ TOP2B Q02880 2/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391687 1.00 ADRB2 (0.61) ADRB2KCNH2GSK3BKDM4EALDH1A1
SCHEMBL1342473 0.96 ADRB2 (0.56) ADRB2KCNH2GSK3BKDM4EALDH1A1
SCHEMBL12586937 0.96 ADRB2 (0.56) ADRB2KCNH2GSK3BKDM4EALDH1A1
SCHEMBL31619099 0.92 ADRB2 (0.52) ADRB2KCNH2GSK3BKDM4EALDH1A1
SCHEMBL31619100 0.92 ADRB2 (0.52) ADRB2KCNH2GSK3BKDM4EALDH1A1
SCHEMBL28414684 0.92 ADRB2 (0.61) ADRB2KCNH2GSK3BKDM4EALDH1A1
SCHEMBL9264733 0.91 ADRB2 (0.51) ADRB2KCNH2GSK3BKDM4EALDH1A1
SCHEMBL28413965 0.91 ADRB2 (0.55) ADRB2KCNH2GSK3BKDM4EALDH1A1
SCHEMBL2844967 0.90 ADRB2 (0.68) ADRB2KCNH2KDM4EALDH1A1HPGD
SCHEMBL29492858 0.90 ADRB2 (0.68) ADRB2KCNH2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115536658-B Preparation method of moxifloxacin hydrochloride monohydrate 天方药业有限公司 2024-06-28 — — CN claimed
CN-115536658-A Preparation method of moxifloxacin hydrochloride monohydrate 天方药业有限公司 2022-12-30 — — CN claimed
CN-114989165-A Compound or composition for resisting retention bacteria and biofilm bacteria and application thereof 青岛大学附属医院 2022-09-02 — — CN claimed
CN-110794046-B Method for detecting 2,4, 5-trifluoro-3-methoxybenzoyl chloride in moxifloxacin intermediate 珠海润都制药股份有限公司 2022-05-06 — — CN claimed
CN-110143959-B Preparation method of moxifloxacin hydrochloride 广西两面针亿康药业股份有限公司 2022-04-26 — — CN claimed
CN-114213392-A Balofloxacin raw material medicine and preparation process thereof 华裕(无锡)制药有限公司 2022-03-22 — — CN claimed
CN-111855848-B Method for analyzing genotoxic impurities in moxifloxacin hydrochloride starting material 山东省食品药品检验研究院 2022-02-18 — — CN claimed
CN-113321652-A Boron removing method of moxifloxacin hydrochloride and preparation method of moxifloxacin hydrochloride pure product 山东鲁抗医药股份有限公司 2021-08-31 — — CN claimed
CN-113121525-A Method for synthesizing moxifloxacin hydrochloride oxidation impurities 北京康派森医药科技有限公司 2021-07-16 — — CN claimed
CN-110878082-B Gatifloxacin and its synthesis method 怀化学院 2021-06-01 — — CN claimed
CN-108088930-B Detection method of quinoline carboxylic acid ethyl ester or/and related substances thereof 成都百裕制药股份有限公司 2021-02-26 — — CN claimed
CN-112225735-A Preparation method of moxifloxacin hydrochloride 北京四环生物制药有限公司 2021-01-15 — — CN claimed
CN-111855848-A Method for analyzing genotoxic impurities in moxifloxacin hydrochloride starting material 山东省食品药品检验研究院 2020-10-30 — — CN claimed
CN-111514125-A Composition containing quinolone compound and edetic acid compound 中山万汉制药有限公司 2020-08-11 — — CN claimed
CN-111150734-A Compositions containing mixtures of quinolinone derivatives and uses thereof 黄泳华 2020-05-15 — — CN claimed
CN-110981874-A Preparation method of moxifloxacin hydrochloride 北京四环生物制药有限公司 2020-04-10 — — CN claimed
CN-110878082-A Gatifloxacin and its synthesis method 怀化学院 2020-03-13 — — CN claimed
CN-103012452-A Preparation method for moxifloxacin and hydrochloride thereof ZHEJIANG NHU CO LTD 2013-04-03 — — CN claimed
US-20090259041-A1 QUINOLINE CARBOXYLIC ACID-O,O BIS-ACYLOXY BORATE AND PROCESS OF MAKING SATYANARAYANA CHAVA 2009-10-15 — — US claimed
US-20060264635-A1 Process for the preparation of moxifloxacin hydrochloride MATRIX LABORATORIES LTD. (IN) 2006-11-23 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264635-A1 Process for the preparation of moxifloxacin hydrochloride CYP4X1, CYP4B1, CYP3A4 ADRB2 2807/4885KCNH2 525/4885GSK3B 3132/4885
US-20090259041-A1 QUINOLINE CARBOXYLIC ACID-O,O BIS-ACYLOXY BORATE AND PROCESS OF MAKING HAO1, DAO, HAO2 ADRB2 2341/4885KCNH2 929/4885GSK3B 3993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.